Cell Source, Inc.
CLCS · OTC
12/31/2024 | 9/30/2024 | 6/30/2024 | 3/31/2024 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | – | – | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | $0 | $0 | $0 | $0 |
| % Margin | – | – | – | – |
| R&D Expenses | $0 | $0 | $1 | $0 |
| G&A Expenses | $0 | $0 | $0 | $1 |
| SG&A Expenses | $0 | $0 | $0 | $1 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | -$0 |
| Operating Expenses | $1 | $1 | $1 | $1 |
| Operating Income | -$1 | -$1 | -$1 | -$1 |
| % Margin | – | – | – | – |
| Other Income/Exp. Net | $0 | -$1 | -$0 | -$0 |
| Pre-Tax Income | -$1 | -$1 | -$1 | -$1 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$1 | -$1 | -$1 | -$1 |
| % Margin | – | – | – | – |
| EPS | -0.021 | -0.042 | -0.045 | -0.04 |
| % Growth | 49.6% | 6.5% | -12.9% | – |
| EPS Diluted | -0.021 | -0.042 | -0.045 | -0.04 |
| Weighted Avg Shares Out | 45 | 42 | 41 | 41 |
| Weighted Avg Shares Out Dil | 45 | 42 | 41 | 41 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $0 | $1 | $0 | $0 |
| Depreciation & Amortization | $0 | -$0 | $0 | $0 |
| EBITDA | -$0 | -$1 | -$1 | -$1 |
| % Margin | – | – | – | – |